AstraZeneca secures licence for CSPC weight-loss candidates in up-to-$18.5 billion agreement
AstraZeneca has obtained global rights (excluding certain Chinese territories) to several of CSPC Pharmaceutical Group's experimental obesity therapies under a deal that carries $1.2 billion in upfront consideration and up to $17.3 billion in milestone payments. The agreement expands an existing collaboration between the two firms, covers developme…